Consequently,
Chikungunya, mpox, oropouche virus …:
Like every year at the beginning of summer. In addition, the High Council of Public Health updates the recommendations for health professionals (doctors, nurses, midwives and pharmacists) so that they can advise travelers, whether in consultation, in international vaccinations, pharmacy or even occupational medicine.
Among the new features. In addition, the HCSP takes stock of the two vaccines against le chkwunka Available in people 12 and over, IXCHIQ, alive attenuated, and Vimkunya, recombinant vaccine based on VLP technology, still not reimbursed, both administered intra-muscularly at least 14 days before departure, and regardless of the history of Chikungunya.
IXCHIQ. Moreover, is contraindicated in people over 65, in immunocompromised people and in the event of hypersensitivity to the active ingredient or an excipient. For example, It is not recommended in pregnant and breastfeeding women. In addition, Vimkunya is an alternative for immunocompromised. Similarly, immunocompetent; chikungunya, mpox, oropouche virus … It is contraindicated in the event of hypersensitivity to the active ingredient or an excipient. Furthermore, Nor is it recommended in pregnant and lactating women for lack of data.
An individualized vaccine strategy on age. Furthermore, comorbidities for dengue – Chikungunya, mpox, oropouche virus …
From May, the HCSP had unveiled its recommendations for the dengue, whose vaccination is to be considered according to the length of stay in endemic or epidemic zone, personal history of dengue and comorbidities of the traveler. Similarly, Qdenga (Takeda laboratories). Therefore, the only vaccine available against this arbovirosis in France from the age of 4, is recommended only: in the event of a stay of more than four weeks or repeated stays in an area where the incidence rate is greater than 100,000 people; Or stay, whatever the duration, in an area where an epidemic is proven.
The HCSP encourages. However, if it is not possible to postpone chikungunya, mpox, oropouche virus … the trip, an individualized vaccine strategy according to age and the presence of comorbidities known to increase the risk of serious dengue. Among people aged 6 to 60 with comorbidities, it is recommended to vaccinate independently of the personal history of dengue. In those over 60 with comorbidities. HCSP is less incentive, indicating that vaccination can be “Considered, as part of a shared medical decision”regardless of the personal history of dengue. As for people 6. over without comorbidities, there too, vaccination can be “ envisaged, as part of a shared medical decision ”but only in subjects with personal history of dengue (PCR DenV and/or AG NS1, evocative clinical history during an epidemic, positive DenV serology).
Vaccination of caregivers at risk of exposure of the CLADE I MPOX
For the mpoxvaccination must be proposed to travelers with risky sexual practices. in accordance with national recommendations (HSH, Trans with chikungunya, mpox, oropouche virus … multiple sexual partners, prostitution, etc.) but also (novelty) to travelers who go to the active circulation area of CLADE I MPOX. when they are caregivers and humanitarian workers at risk of exposure; Or at risk of exposure according to the living conditions on site (promiscuity, division of bedding, compliance with barrier measures).
Two vaccines are currently available. interchangeable, Imvoxex and Jynneos, with a vaccine diagram with two doses, or even three for immunocompromised. In the event of an imminent departure not making possible the complete realization of the vaccination scheme. the administration of a dose offers a satisfactory level of protection, it is specified.
Like last year. for the measlesit is recommended to check and update travelers’ vaccination; And a third dose is recommended for people who started their vaccination before their first birthday, as in France where almost 700 cases have already been declared.
For them Invasive chikungunya, mpox, oropouche virus … infections in Méningococci (IIM)in France. the vaccination strategy has been reviewed, it is recalled: ACWY tetravalent vaccination is compulsory for infants under two years of age with a diagram with two injections (6 and 12 months of life). It is recommended in children from 2 years to 4 years old. (transitional measurement of vaccination catch -up) and adolescents from 11 to 14 years old regardless of their vaccination status, then in the 15 to 24 years. Vaccination against IIM of serogroup B by the BexSero vaccine is compulsory for infants under two years of age. A catch-up is recommended in children aged 2 to 5 years and 15-24 year olds (with whom it is now reimbursed).
For travelers. tetravalent vaccination against IIMs is recommended to people going to an endemic area of IIM A, C, W, Y, in particular the “meningitis belt” located in sub -Saharan Africa, in particular to chikungunya, mpox, oropouche virus … carry out an activity in the health sector. In addition. some countries have a different vaccine policy for IIM from that of France in the general population, which can motivate vaccination during prolonged stays, in particular adolescents. The HCSP also recalls the rules for pilgrimages to Mecca.
A chapter was added following the geographic extension of oropouche virus infections in Latin America. the Caribbean, and to the identification of cases of maternity-fetal transmissions. He recalls the anti -fiercelle personal protection measures. and advises against the journey of pregnant women, or with a pregnancy project.
Finally, cards concerning malaria, arboviroses, polio, tuberculosis or tick encephalitis are updated.
Chikungunya, mpox, oropouche virus …
IXCHIQ’s side effects under the eye of the ANSM
According to the pharmacovigilance survey of the national drug safety agency. between March 7 and June 2, 2025, 47 cases of undesirable effects of the IXCHIQ vaccine were declared chikungunya, mpox, oropouche virus … in France (mostly, in meeting patients, on average aged 74), including 18 serious cases comprising 3 deaths of polypathological patients. The symptoms reported were similar to those of a serious form of infection with the chikungunya virus. There would be a link between the vaccine and the serious side effects for 9 of these patients. For one of the three deaths. the link with Ixchiq “Seems to be very likely, given the chronology, the patient’s symptoms and the results of the biological examinations collected. To date, it is not possible to establish a link between the vaccine and the other two deaths ”.
Investigations are underway at European level on potential signals concerning the risk of encephalopathy. encephalitis in elderly people with comorbidities, the risk of remote fall in vaccination and the risk of thrombotic microangiopathy.
Further reading: The brain of the parakeets, an unexpected model to reveal the secrets of human language – A great advance in the treatment of Alzheimer’s? – IA drones are revolutionizing the fight against malaria [Business Africa] – Doctors tell her that she suffers from stomach burns, it was cancer – HIV/AIDS: REGAP + calls on families to enter the fight | Lunion.ga.
